Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Abstract

Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone.

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN: 0732-183X

ISSN (Print): 0732-183X

Publication date (Electronic): Jul 15 2003

Volume: 21

Issue: 14

Affiliations

[1 ] University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA. [e-mail].

Article

Publisher Item ID: JCO.2003.11.136

DOI: 10.1200/JCO.2003.11.136

PubMed ID: 12860938

SO-VID: a3280ea9-14c6-495e-9232-828419cb2c91